Analyst Coverage: Piper Sandler analyst Kelsey Goodwin has begun coverage of Bicara Therapeutics.
Rating: The stock has been given an Overweight rating, indicating a positive outlook.
Price Target: A price target of $36 has been set for Bicara Therapeutics.
Market Implications: This rating and target suggest potential growth opportunities for investors in the company.
BCAX
$18.62+Infinity%1D
Analyst Views on BCAX
Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 32.40 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 32.40 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.360
Low
11.00
Averages
32.40
High
48.00
Current: 18.360
Low
11.00
Averages
32.40
High
48.00
JonesResearch
NULL -> Buy
initiated
$22
2025-09-09
Reason
JonesResearch
Price Target
$22
2025-09-09
initiated
NULL -> Buy
Reason
JonesResearch initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $22 price target. The firm says clinical data from Keytruda combinations with bispecific antibodies of Bicara and Merus (MRUS) showed more than doubling of clinical benefits in head and neck cancer. Bicara's "differentiated drug profile offers a compelling investment case," the analyst tells investors in a research note. JonesResearch views the shares as oversold at current levels.
H.C. Wainwright
Robert Burns
Buy
downgrade
$41 -> $40
2025-08-22
Reason
H.C. Wainwright
Robert Burns
Price Target
$41 -> $40
2025-08-22
downgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns lowered the firm's price target on Bicara Therapeutics to $40 from $41 and keeps a Buy rating on the shares following the Q2 report. The firm is factoring in higher long-term operating expenses.
Piper Sandler
Kelsey Goodwin
Overweight
initiated
$36
2025-08-19
Reason
Piper Sandler
Kelsey Goodwin
Price Target
$36
2025-08-19
initiated
Overweight
Reason
Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics with an Overweight rating and $36 price target. The firm's channel checks highlighted a favorable view on Bicara's patient selection strategy for the pivotal FORTIFi-HN01, ficera's potentially differentiated mDOR, the importance of continued follow-up in relapsed metastatic head and neck squamous cell cancer, and the overall perception that the large market will likely be split longer term, the analyst tells investors in a research note. Piper sees the recent pullback as offering a highly attractive entry point.
Piper Sandler
Kelsey Goodwin
initiated
$36
2025-08-18
Reason
Piper Sandler
Kelsey Goodwin
Price Target
$36
2025-08-18
initiated
Reason
Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics with an Overweight rating and $36 price target.
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
